Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: The SHR strain

Frontiers in Pharmacology

Volumn 5 FEB, Issue , 2014, Pages

  Levin, Raquel ^a   Peres, Fernanda F ^a   Almeida, Valéria ^a   Calzavara, Mariana B ^a   Zuardi, Antonio W ^b,c   Hallak, Jaime E C ^b,c   Crippa, José Alexandre S ^b,c   Abílio, Vanessa C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Ministério de Ciência Tecnologia e Inovação Salvador   (Brazil)

Author keywords

Animal model; Cannabinoid drugs; PPI; Schizophrenia; SHR

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; ENDOCANNABINOID; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; HYPEREKPLEXIA; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PREPULSE INHIBITION; SCHIZOPHRENIA; SENSORIMOTOR NEUROPATHY; SENSORY GATING; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT RESPONSE; WISTAR RAT;

EID: 84895529159     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00010     Document Type: Article

References (118)

1. Alonso, R., Voutsinos, B., Fournier, M., Labie, C., Steinberg, R., Souilhac, J., et al. (1999). Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience 91, 607-620. doi: 10.1016/S0306-4522(98)00675-7.
2. Ballmaier, M., Bortolato, M., Rizzetti, C., Zoli, M., Gessa, G., Heinz, A., et al. (2007). Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 32, 2098-2107. doi: 10.1038/sj.npp.1301344.
3. 2 receptor responses by an anandamide transport inhibitor. J. Neurosci. 20, 3401-3407.
4. Bergamaschi, M. M., Queiroz, R. H., Zuardi, A. W., and Crippa, J. A. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr. Drug Saf. 6, 237-249. doi: 10.2174/157488611798280924.
5. Bersani, G., Orlandi, V., Kotzalidis, G. D., and Pancheri, P. (2002). Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur. Arch. Psychiatry Clin. Neurosci. 252, 86-92. doi: 10.1007/s00406-002-0366-5.
6. Bhattacharyya, S., Fusar-Poli, P., Borgwardt, S., Martin-Santos, R., Nosarti, C., O'Carroll, C., et al. (2009). Modulation of mediotemporal and ventrostriatal function in humans by Δ 9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch. Gen. Psychiatry 66, 442-451. doi: 10.1001/archgenpsychiatry.2009.17.
7. Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., et al. (2010). Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764-774. doi: 10.1038/npp.2009.184.
8. Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., et al. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845-852. doi: 10.1038/sj.bjp.0704327.
9. Bizot, J. C., Chenault, N., Houze, B., Herpin, A., David, S., Pothion, S., et al. (2007). Methylphenidate reduces impulsive behaviour in juvenile Wistar rats, but not in adult Wistar, SHR and WKY rats. Psychopharmacology (Berl.) 193, 215-223. doi: 10.1007/s00213-007-0781-4.
10. Black, M. D., Stevens, R. J., Rogacki, N., Featherstone, R. E., Senyah, Y., Giardino, O., et al. (2011). AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl.) 215, 149-163. doi: 10.1007/s00213-010-2124-0.
11. Borgwardt, S. J., Allen, P., Bhattacharyya, S., Fusar-Poli, P., Crippa, J. A., Seal, M. L., et al. (2008). Neural basis of Δ-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol. Psychiatry 64, 966-973. doi: 10.1016/j.biopsych.2008.05.011.
12. Bortolato, M., Campolongo, P., Mangieri, R. A., Scattoni, M. L., Frau, R., Trezza, V., et al. (2006). Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 31, 2652-2659. doi: 10.1038/sj.npp.1301061.
13. Braff, D. L., and Geyer, M. A. (1990). Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 47, 181-188. doi: 10.1001/archpsyc.1990.01810140081011.
14. Braff, D. L., Grillon, C., and Geyer, M. A. (1992). Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry 49, 206-215. doi: 10.1001/archpsyc.1992.01820030038005.
15. Braff, D. L., Swerdlow, N. R., and Geyer, M. A. (1999). Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am. J. Psychiatry 156, 596-602.
16. Brzozka, M. M., Fischer, A., Falkai, P., and Havemann-Reinecke, U. (2011). Acute treatment with cannabinoid receptor agonist WIN55212.2 improves prepulse inhibition in psychosocially stressed mice. Behav. Brain Res. 218, 280-287. doi: 10.1016/j.bbr.2010.11.003.
17. Calzavara, M. B., Levin, R., Medrano, W. A., Almeida, V., Sampaio, A. P., Barone, L. C., et al. (2011). Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats. Behav. Brain Res. 225, 15-22. doi: 10.1016/j.bbr.2011.06.026.
18. Calzavara, M. B., Medrano, W. A., Levin, R., Kameda, S. R., Andersen, M. L., Tufik, S., et al. (2009). Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia? Schizophr. Bull. 35, 748-759. doi: 10.1093/schbul/sbn006.
19. Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., and Guimaraes, F. S. (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367, 3364-3378. doi: 10.1098/rstb.2011.0389.
20. Crippa, J. A. S., Zuardi, A. W., and Hallak, J. E. C. (2010). Therapeutical use of the cannabinoids in psychiatry. Rev. Bras. Psiquiatr. 32, 556-566. doi: 10.1590/S1516-44462010000500009.
21. Csomor, P. A., Yee, B. K., Vollenweider, F. X., Feldon, J., Nicolet, T., and Quednow, B. B. (2008). On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behav. Neurosci. 122, 885-900. doi: 10.1037/0735-7044.122.4.885.
22. Dalton, V. S., Long, L. E., Weickert, C. S., and Zavitsanou, K. (2011). Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 36, 1620-1630. doi: 10.1038/npp.2011.43.
23. Dean, B., Sundram, S., Bradbury, R., Scarr, E., and Copolov, D. (2001). Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15. doi: 10.1016/S0306-4522(00)00552-2.
24. De Marchi, N., De Petrocellis, L., Orlando, P., Daniele, F., Fezza, F., and Di Marzo, V. (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2, 5. doi: 10.1186/1476-511X-2-5.
25. Dissanayake, D. W., Mason, R., and Marsden, C. A. (2013). Sensory gating, cannabinoids and schizophrenia. Neuropharmacology 67, 66-77. doi: 10.1016/j.neuropharm.2012.10.011.
26. D'Souza, D. C., Sewell, R. A., and Ranganathan, M. (2009). Cannabis and psychosis/schizophrenia: human studies. Eur. Arch. Psychiatry Clin. Neurosci. 259, 413-431. doi: 10.1007/s00406-009-0024-2.
27. Ferguson, S. A., and Cada, A. M. (2003). A longitudinal study of short-and long-term activity levels in male and female spontaneously hypertensive, Wistar-Kyoto, and Sprague-Dawley rats. Behav. Neurosci. 117, 271-282. doi: 10.1037/0735-7044.117.2.271.
28. Ferguson, S. A., and Cada, A. M. (2004). Spatial learning/memory and social and nonsocial behaviors in the spontaneously hypertensive, Wistar-Kyoto and Sprague-Dawley rat strains. Pharmacol. Biochem. Behav. 77, 583-594. doi: 10.1016/j.pbb.2003.12.014.
29. Fernandez-Espejo, E., and Galan-Rodriguez, B. (2004). Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor. Psychopharmacology (Berl.) 175, 220-224. doi: 10.1007/s00213-004-1851-5.
30. Ferrer, B., Gorriti, M. A., Palomino, A., Gornemann, I., De Diego, Y., Bermudez-Silva, F. J., et al. (2007). Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies. Eur. J. Pharmacol 559, 180-183. doi: 10.1016/j.ejphar.2007.01.009.
31. Fogaca, M. V., Aguiar, D. C., Moreira, F. A., and Guimaraes, F. S. (2012). The endocannabinoid and endovanilloid systems interact in the rat prelimbic medial prefrontal cortex to control anxiety-like behavior. Neuropharmacology 63, 202-210. doi: 10.1016/j.neuropharm.2012.03.007.
32. Gallinat, J., Rentzsch, J., and Roser, P. (2012). Neurophysiological effects of cannabinoids: implications for psychosis research. Curr. Pharm. Des. 18, 4938-4949. doi: 10.2174/138161212802884582.
33. Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., et al. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108-2114. doi: 10.1038/sj.npp.1300558.
34. Giuffrida, A., Rodriguez De Fonseca, F., Nava, F., Loubet-Lescoulie, P., and Piomelli, D. (2000). Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur. J. Pharmacol. 408, 161-168. doi: 10.1016/S0014-2999(00)00786-X.
35. Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., et al. (2005). Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38, 301-311. doi: 10.1055/s-2005-916185.
36. Grillon, C., Ameli, R., Charney, D. S., Krystal, J., and Braff, D. (1992). Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol. Psychiatry 32, 939-943. doi: 10.1016/0006-3223(92)90183-Z.
37. Grlie, L. (1976). A comparative study on some chemical and biological characteristics of various samples of cannabis resin. Bull. Narc. 14, 37-46.
38. Guidali, C., Vigano, D., Petrosino, S., Zamberletti, E., Realini, N., Binelli, G., et al. (2011). Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Int. J. Neuropsychopharmacol. 14, 17-28. doi: 10.1017/S1461145710000209.
39. Guimaraes, V. M., Zuardi, A. W., Del Bel, E. A., and Guimaraes, F. S. (2004). Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci. 75, 633-638. doi: 10.1016/j.lfs.2004.01.015.
40. Gururajan, A., Taylor, D. A., and Malone, D. T. (2011). Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia. Behav. Brain Res. 222, 299-308. doi: 10.1016/j.bbr.2011.03.053.
41. Hill, M. N., and Gorzalka, B. B. (2004). Enhancement of anxiety-like responsiveness to the cannabinoid CB1 receptor agonist HU-210 following chronic stress. Eur. J. Pharmacol. 499, 291-295. doi: 10.1016/j.ejphar.2004.06.069.
42. Johnson, M. L., Ely, D. L., and Turner, M. E. (1992). Genetic divergence between the Wistar-Kyoto rat and the spontaneously hypertensive rat. Hypertension 19, 425-427. doi: 10.1161/01.HYP.19.5.425.
43. Kedzior, K. K., and Martin-Iverson, M. T. (2006). Chronic cannabis use is associated with attention-modulated reduction in prepulse inhibition of the startle reflex in healthy humans. J. Psychopharmacol. 20, 471-484. doi: 10.1177/0269881105057516.
44. Kelly, D. L., Gorelick, D. A., Conley, R. R., Boggs, D. L., Linthicum, J., Liu, F., et al. (2011). Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J. Clin. Psychopharmacol. 31, 86-91. doi: 10.1097/JCP.0b013e318204825b.
45. Kinkead, B., Selz, K. A., Owens, M. J., and Mandell, A. J. (2006). Algorithmically designed peptides ameliorate behavioral defects in animal model of ADHD by an allosteric mechanism. J. Neurosci. Methods 151, 68-81. doi: 10.1016/j.jneumeth.2005.07.015.
46. Koethe, D., Hoyer, C., and Leweke, F. M. (2009). The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berl.) 206, 551-561. doi: 10.1007/s00213-009-1591-7.
47. Krystal, J. H., D'Souza, D. C., Petrakis, I. L., Belger, A., Berman, R. M., Charney, D. S., et al. (1999). NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatry 7, 125-143.
48. Levin, R., Almeida, V., Peres, F. F., Calzavara, M. B., Da Silva, N. D., Suiama, M. A., et al. (2012). Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Curr. Pharm. Des. 18, 4960-4965. doi: 10.2174/138161212802884735.
49. Levin, R., Calzavara, M. B., Santos, C. M., Medrano, W. A., Niigaki, S. T., and Abilio, V. C. (2011). Spontaneously Hypertensive Rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1748-1752. doi: 10.1016/j.pnpbp.2011.06.003.
50. Leweke, F. M., Gerth, C. W., and Klosterkotter, J. (2004). Cannabis-associated psychosis: current status of research. CNS Drugs 18, 895-910. doi: 10.2165/00023210-200418130-00005.
51. Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., and Piomelli, D. (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665-1669. doi: 10.1097/00001756-199906030-00008.
52. Leweke, F. M., Koethe, D., Gerth, C. W., Nolden, B. M., Schreiber, D., Gross, S., et al. (2007). Cannabidiol as an antipsychotic agent. Eur. Psychiatry 22, S21. doi: 10.1016/j.eurpsy.2007.01.084.
53. Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., et al. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2, e94. doi: 10.1038/tp.2012.15.
54. Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., and Emrich, H. M. (2000). Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol. Biochem. Behav. 66, 175-181. doi: 10.1016/S0091-3057(00)00201-X.
55. Long, L. E., Chesworth, R., Huang, X. F., Wong, A., Spiro, A., Mcgregor, I. S., et al. (2012). Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLoS ONE 7:e34129. doi: 10.1371/journal.pone.0034129.
56. Long, L. E., Malone, D. T., and Taylor, D. A. (2006). Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31, 795-803. doi: 10.1038/sj.npp.1300838.
57. Malone, D. T., Jongejan, D., and Taylor, D. A. (2009). Cannabidiol reverses the reduction in social interaction produced by low dose Δ 9-tetrahydrocannabinol in rats. Pharmacol. Biochem. Behav. 93, 91-96. doi: 10.1016/j.pbb.2009.04.010.
58. Malone, D. T., Long, L. E., and Taylor, D. A. (2004). The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice. Pharmacol. Biochem. Behav. 77, 839-845. doi: 10.1016/j.pbb.2004.02.010.
59. Malone, D. T., and Taylor, D. A. (2006). The effect of Δ 9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behav. Brain Res. 166, 101-109. doi: 10.1016/j.bbr.2005.07.009.
60. Martin, R. S., Secchi, R. L., Sung, E., Lemaire, M., Bonhaus, D. W., Hedley, L. R., et al. (2003). Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berl.) 165, 128-135.
61. Mathias, C. W., Blumenthal, T. D., Dawes, M. A., Liguori, A., Richard, D. M., Bray, B., et al. (2011). Failure to sustain prepulse inhibition in adolescent marijuana users. Drug Alcohol Depend. 116, 110-116. doi: 10.1016/j.drugalcdep.2010.11.020.
62. Meltzer, H. Y., Arvanitis, L., Bauer, D., and Rein, W. (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 161, 975-984. doi: 10.1176/appi.ajp.161.6.975.
63. Metna-Laurent, M., Soria-Gomez, E., Verrier, D., Conforzi, M., Jego, P., Lafenetre, P., et al. (2012). Bimodal control of fear-coping strategies by CB1 cannabinoid receptors. J. Neurosci. 32, 7109-7118. doi: 10.1523/JNEUROSCI.1054-12.2012.
64. Moreira, F. A., and Guimaraes, F. S. (2005). Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur. J. Pharmacol. 512, 199-205. doi: 10.1016/j.ejphar.2005.02.040.
65. Moreira, F. A., and Lutz, B. (2008). The endocannabinoid system: emotion, learning and addiction. Addict. Biol. 13, 196-212. doi: 10.1111/j.1369-1600.2008.00104.x.
66. Newell, K. A., Deng, C., and Huang, X. F. (2006). Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res. 172, 556-560. doi: 10.1007/s00221-006-0503-x.
67. Okamoto, K., and Aoki, K. (1963). Development of a strain of spontaneously hypertensive rats. Jpn. Circ. J. 27, 282-293. doi: 10.1253/jcj.27.282.
68. Palmer, A. A., Dulawa, S. C., Mottiwala, A. A., Conti, L. H., Geyer, M. A., and Printz, M. P. (2000). Prepulse startle deficit in the Brown Norway rat: a potential genetic model. Behav. Neurosci. 114, 374-388. doi: 10.1037/0735-7044.114.2.374.
69. Pamplona, F. A., and Takahashi, R. N. (2006). WIN 55212-2 impairs contextual fear conditioning through the activation of CB1 cannabinoid receptors. Neurosci. Lett. 397, 88-92. doi: 10.1016/j.neulet.2005.12.026.
70. Pare, W. P. (1992). Learning behavior, escape behavior, and depression in an ulcer susceptible rat strain. Integr. Physiol. Behav. Sci. 27, 130-141. doi: 10.1007/BF02698502.
71. Pare, W. P. (1994). Open field, learned helplessness, conditioned defensive burying, and forced-swim tests in WKY rats. Physiol. Behav. 55, 433-439. doi: 10.1016/0031-9384(94)90097-3.
72. Peralta, V., and Cuesta, M. J. (1992). Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr. Scand. 85, 127-130. doi: 10.1111/j.1600-0447.1992.tb01456.x.
73. 9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199-215. doi: 10.1038/sj.bjp.0707442.
74. Polissidis, A., Galanopoulos, A., Naxakis, G., Papahatjis, D., Papadopoulou-Daifoti, Z., and Antoniou, K. (2013). The cannabinoid CB1 receptor biphasically modulates motor activity and regulates dopamine and glutamate release region dependently. Int. J. Neuropsychopharmacol. 16, 393-403. doi: 10.1017/S1461145712000156.
75. Quednow, B. B., Frommann, I., Berning, J., Kuhn, K. U., Maier, W., and Wagner, M. (2008). Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. Biol. Psychiatry 64, 766-773. doi: 10.1016/j.biopsych.2008.04.019.
76. Quednow, B. B., Kuhn, K. U., Hoenig, K., Maier, W., and Wagner, M. (2004). Prepulse inhibition and habituation of acoustic startle response in male MDMA ('ecstasy') users, cannabis users, and healthy controls. Neuropsychopharmacology 29, 982-990. doi: 10.1038/sj.npp.1300396.
77. Quednow, B. B., Wagner, M., Westheide, J., Beckmann, K., Bliesener, N., Maier, W., et al. (2006). Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine. Biol. Psychiatry 59, 536-545. doi: 10.1016/j.biopsych.2005.07.012.
78. Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240-244. doi: 10.1016/0014-5793(94)00773-X.
79. Robertson, G. S., and Fibiger, H. C. (1992). Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46, 315-328. doi: 10.1016/0306-4522(92)90054-6.
80. Roser, P., and Haussleiter, I. S. (2012). Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. Curr. Pharm. Des. 18, 5141-5155. doi: 10.2174/138161212802884690.
81. Roser, P., Haussleiter, I. S., Chong, H. J., Maier, C., Kawohl, W., Norra, C., et al. (2011). Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia. Psychopharmacology (Berl.) 218, 611-620. doi: 10.1007/s00213-011-2352-y.
82. Roser, P., Vollenweider, F. X., and Kawohl, W. (2010). Potential antipsychotic properties of central cannabinoid CB1 receptor antagonists. World J. Biol. Psychiatry 11, 208-219. doi: 10.3109/15622970801908047.
83. Russell, V. A. (2007). Neurobiology of animal models of attention-deficit hyperactivity disorder. J. Neurosci. Methods 161, 185-198. doi: 10.1016/j.jneumeth.2006.12.005.
84. Russo, E. B., Burnett, A., Hall, B., and Parker, K. K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30, 1037-1043. doi: 10.1007/s11064-005-6978-1.
85. Sagvolden, T., Metzger, M. A., Schiorbeck, H. K., Rugland, A. L., Spinnangr, I., and Sagvolden, G. (1992). The spontaneously hypertensive rat (SHR) as an animal model of childhood hyperactivity (ADHD): changed reactivity to reinforcers and to psychomotor stimulants. Behav. Neural. Biol. 58, 103-112. doi: 10.1016/0163-1047(92)90315-U.
86. Sagvolden, T., and Sergeant, J. A. (1998). Attention deficit/hyperactivity disorder-from brain dysfunctions to behaviour. Behav. Brain Res. 94, 1-10. doi: 10.1016/S0166-4328(97)00164-2.
87. Sams-Dodd, F. (1998). A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology 18, 293-304. doi: 10.1016/S0893-133X(97)00161-9.
88. Schlicker, E., and Kathmann, M. (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22, 565-572. doi: 10.1016/S0165-6147(00)01805-8.
89. Schneider, M., and Koch, M. (2002). The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats. Behav. Pharmacol. 13, 29-37. doi: 10.1097/00008877-200202000-00003.
90. Schwarcz, G., Karajgi, B., and Mccarthy, R. (2009). Synthetic Δ-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. J. Clin. Psychopharmacol. 29, 255-258. doi: 10.1097/JCP.0b013e3181a6bc3b.
91. Seillier, A., Advani, T., Cassano, T., Hensler, J. G., and Giuffrida, A. (2010). Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int. J. Neuropsychopharmacol. 13, 373-386. doi: 10.1017/S146114570999023X.
92. Sewell, R. A., Skosnik, P. D., Garcia-Sosa, I., Ranganathan, M., and D'Souza, D. C. (2010). Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia. Rev. Bras. Psiquiatr. 32(Suppl. 1), S15-S30. doi: 10.1590/S1516-44462010000500005.
93. Spano, M. S., Fadda, P., Frau, R., Fattore, L., and Fratta, W. (2010). Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. Eur. Neuropsychopharmacol. 20, 25-36. doi: 10.1016/j.euroneuro.2009.09.004.
94. Spano, M. S., Fattore, L., Cadeddu, F., Fratta, W., and Fadda, P. (2012). Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. Psychopharmacology (Berl.) 225, 531-542. doi: 10.1007/s00213-012-2839-1.
95. St Lezin, E., Simonet, L., Pravenec, M., and Kurtz, T. W. (1992). Hypertensive strains and normotensive 'control' strains. How closely are they related? Hypertension 19, 419-424. doi: 10.1161/01.HYP.19.5.419.
96. Swerdlow, N. R., Braff, D. L., and Geyer, M. A. (2000). Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav. Pharmacol. 11, 185-204. doi: 10.1097/00008877-200006000-00002.
97. Swerdlow, N. R., Braff, D. L., Taaid, N., and Geyer, M. A. (1994). Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry 51, 139-154. doi: 10.1001/archpsyc.1994.03950020063007.
98. Swerdlow, N. R., Geyer, M. A., and Braff, D. L. (2001). Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl.) 156, 194-215. doi: 10.1007/s002130100799.
99. Swerdlow, N. R., Kuczenski, R., Goins, J. C., Crain, S. K., Ma, L. T., Bongiovanni, M. J., et al. (2005). Neurochemical analysis of rat strain differences in the startle gating-disruptive effects of dopamine agonists. Pharmacol. Biochem. Behav. 80, 203-211. doi: 10.1016/j.pbb.2004.11.002.
100. Ujike, H., and Morita, Y. (2004). New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J. Pharmacol. Sci. 96, 376-381. doi: 10.1254/jphs.FMJ04003X4.
101. van den Bergh, F. S., Bloemarts, E., Chan, J. S., Groenink, L., Olivier, B., and Oosting, R. S. (2006). Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder. Pharmacol. Biochem. Behav. 83, 380-390. doi: 10.1016/j.pbb.2006.02.018.
102. van den Buuse, M. (2004). Prepulse inhibition of acoustic startle in spontaneously hypertensive rats. Behav. Brain Res. 154, 331-337. doi: 10.1016/j.bbr.2004.02.021.
103. Vendruscolo, L. F., Terenina-Rigaldie, E., Raba, F., Ramos, A., Takahashi, R. N., and Mormede, P. (2006). A QTL on rat chromosome 7 modulates prepulse inhibition, a neuro-behavioral trait of ADHD, in a Lewis x SHR intercross. Behav. Brain Funct. 2, 21. doi: 10.1186/1744-9081-2-21.
104. Verdoux, H., Tournier, M., and Cougnard, A. (2005). Impact of substance use on the onset and course of early psychosis. Schizophr. Res. 79, 69-75. doi: 10.1016/j.schres.2004.12.008.
105. Viveros, M. P., Marco, E. M., and File, S. E. (2005). Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 81, 331-342. doi: 10.1016/j.pbb.2005.01.029.
106. Wegener, N., Kuhnert, S., Thuns, A., Roese, R., and Koch, M. (2008). Effects of acute systemic and intra-cerebral stimulation of cannabinoid receptors on sensorimotor gating, locomotion and spatial memory in rats. Psychopharmacology (Berl.) 198, 375-385. doi: 10.1007/s00213-008-1148-1.
107. Weike, A. I., Bauer, U., and Hamm, A. O. (2000). Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. Biol. Psychiatry 47, 61-70. doi: 10.1016/S0006-3223(99)00229-2.
108. Weiss, I. C., Di Iorio, L., Feldon, J., and Domeney, A. M. (2000). Strain differences in the isolation-induced effects on prepulse inhibition of the acoustic startle response and on locomotor activity. Behav. Neurosci. 114, 364-373. doi: 10.1037/0735-7044.114.2.364.
109. Winton-Brown, T. T., Allen, P., Bhattacharyya, S., Borgwardt, S. J., Fusar-Poli, P., Crippa, J. A., et al. (2011). Modulation of auditory and visual processing by Δ-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology 36, 1340-1348. doi: 10.1038/npp.2011.17.
110. Xue, Y. Y., Wang, H. N., Xue, F., and Tan, Q. R. (2012). Atypical antipsychotics do not reverse prepulse inhibition deficits in acutely psychotic schizophrenia. J. Int. Med. Res. 40, 1467-1475. doi: 10.1177/147323001204000425.
111. Zamberletti, E., Vigano, D., Guidali, C., Rubino, T., and Parolaro, D. (2012). Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. Int. J. Neuropsychopharmacol. 15, 267-280. doi: 10.1017/S1461145710001185.
112. Zavitsanou, K., Garrick, T., and Huang, X. F. (2004). Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 355-360. doi: 10.1016/j.pnpbp.2003.11.005.
113. Zuardi, A. W. (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr. 30, 271-280. doi: 10.1590/S1516-44462008000300015.
114. Zuardi, A. W., Crippa, J. A., and Hallak, J. E. (2010). Cannabis sativa: the plant that can induce unwanted effects and also treat them. Rev. Bras. Psiquiatr. 32(Suppl. 1), S1-S2.
115. Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., et al. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr. Pharm. Des. 18, 5131-5140. doi: 10.2174/138161212802884681.
116. Zuardi, A. W., Crippa, J. A., Hallak, J. E., Moreira, F. A., and Guimaraes, F. S. (2006). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res. 39, 421-429. doi: 10.1590/S0100-879X2006000400001.
117. Zuardi, A. W., Crippa, J. A., Hallak, J. E., Pinto, J. P., Chagas, M. H., Rodrigues, G. G., et al. (2009). Cannabidiol for the treatment of psychosis in Parkinson's disease. J. Psychopharmacol. 23, 979-983. doi: 10.1177/0269881108096519.
118. Zuardi, A. W., Morais, S. L., Guimaraes, F. S., and Mechoulam, R. (1995). Antipsychotic effect of cannabidiol. J. Clin. Psychiatry 56, 485-486. doi: 10.2174/138161212802884681.